Signal
Apogee Therapeutics secures $1.3 billion funding from Blackstone to advance eczema drug to phase 3
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-27 13:09 UTCUpdated 2026-05-27 15:37 UTC
rss
clinical_trialsbiotech_fundingdrug_developmentr_and_d
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Apogee Therapeutics has secured a substantial financing commitment of up to $1.3 billion from Blackstone Life Sciences to propel its anti-IL-13 antibody treatment for eczema into late-stage clinical development. This milestone comes after encouraging new research data strengthened confidence in the drug's potential. The funding will support the initiation of phase 3 trials, positioning Apogee to challenge existing therapies like Dupixent and Ebglyss in the competitive eczema treatment market.
Entities
Apogee TherapeuticsBlackstone Life Sciences
Score total
0.99
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Recent positive research results have strengthened confidence in the drug's potential.
- Securing large-scale financing is critical to support costly phase 3 trials.
- The timing positions Apogee to compete in a growing market for eczema therapies.
Why it matters
- The $1.3 billion funding enables Apogee to advance a promising eczema drug into late-stage clinical trials.
- The drug targets IL-13, a key pathway in eczema, potentially offering a new treatment option.
- Competition with established therapies like Dupixent could impact the eczema treatment landscape.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Apogee Therapeutics secured up to $1.3 billion in financing from Blackstone Life Sciences to advance its anti-IL-13 antibody for eczema into phase 3 trials.
- New research results have bolstered confidence in Apogee's experimental eczema drug, supporting its progression to late-stage clinical development.
How sources frame it
- Apogee Therapeutics: supportive
Consolidated key facts from two high-quality sources to provide a clear update on Apogee's funding and clinical progress.
All evidence
All evidence
Apogee eczema drugs gets Blackstone backing, heads to Phase 3
BioPharma Dive · biopharmadive.com · 2026-05-27 15:37 UTC
Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.
Fierce Biotech · fiercebiotech.com · 2026-05-27 13:09 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)